Sprifermin (AS902330) in Cartilage Injury Repair (CIR)

NCT ID: NCT01066871

Last Updated: 2016-03-23

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 74 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-03-31
• Study Completion Date: 2013-04-30

Brief Summary

Several people all over the world suffer from cartilage injuries in the knee. Symptoms include pain, joint swelling, and loss of function. Without repair, cartilage injury may ultimately lead to osteoarthritis (OA). Natural healing is poor, and to date treatment is available only for deep cartilage defects involving also the underlying bone. A promising candidate for drug treatment of cartilage injury is sprifermin (AS902330), a recombinant form of the human fibroblast growth factor (FGF) 18.

So far, the drug has been used in subjects with different stages of knee OA in two ongoing studies without emerging safety issues following single and multiple intra-articular injections of ascending doses. However, OA represents late-stage cartilage injury, where repair might be difficult due to diffuse damage, reduced responsiveness of the cartilage, and/or the involvement of other joint structures.

This clinical trial is meant to provide the proof of concept and to identify an efficacious dose of sprifermin (AS902330) for the treatment of adult subjects with acute cartilage injuries of the knee. The first subject for this trial was treated on the 19th of April 2010.

Conditions

Isolated Cartilage Injury of the Knee

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Sprifermin (AS902330) 10 mcg

Group Type: EXPERIMENTAL

Sprifermin (AS902330) 10 mcg

Intervention Type: DRUG

Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.

Sprifermin (AS902330) 30 mcg

Group Type: EXPERIMENTAL

Sprifermin (AS902330) 30 mcg

Intervention Type: DRUG

Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.

Sprifermin (AS902330) 100 mcg

Group Type: EXPERIMENTAL

Sprifermin (AS902330) 100 mcg

Intervention Type: DRUG

Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.

Interventions

Sprifermin (AS902330) 10 mcg

Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.

Intervention Type: DRUG

Sprifermin (AS902330) 30 mcg

Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.

Intervention Type: DRUG

Sprifermin (AS902330) 100 mcg

Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.

Intervention Type: DRUG

Placebo

Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Acute cartilage lesion of ICRS grade 2 to 4 at the femoral condyle of the knee (= target knee)
• Age: 18 to 45 years
• Sex: male or female. Women of childbearing potential (that is, all female subjects after puberty unless they are post-menopausal for at least 2 years or surgically sterile) must have negative serum and urine pregnancy tests at screening and Visit 1, respectively, and must use a highly effective method of contraception.
• History of pain and effusion of the target knee post-injury
• Injury within 4 to 12 weeks prior to 1st treatment with investigational medicinal product (IMP)
• Written informed consent prior to any trial-related activity

Exclusion Criteria

• Personal medical history of osteoarthritis OA in either knee
• Any previous surgery on the target knee
• History of swelling of the target knee along with pain on weight-bearing, or arthroscopy for diagnostic purposes during the 12 months preceding injury
• Corticosteroid (intra-articular) injection into the target knee during the preceding 12 months
• Any other intra-articular injection into the target knee during the preceding 3 months
• Any concurrent injury (for example, arthrolith, anterior cruciate ligament rupture, meniscus tear) of the target knee requiring surgical intervention
• OA or any pre-existing cartilage damage in the target knee, as revealed by MRI
• Legal incapacity or limited legal capacity
• Subjects who are imprisoned or institutionalized by regulatory or court order
• Pregnancy or lactation
• Participation in another clinical trial within the past 30 days
• Any condition or findings in the medical history or in the pre-trial assessments that in the opinion of the Investigator constitutes a risk or contraindication for participation in the trial or that could interfere with the trial objectives, conduct or evaluation
• Known hypersensitivity to the trial treatment or diluents
• Significant renal or hepatic impairment, as indicated by: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) greater than (>) 3 times the upper limit of normal (ULN); total bilirubin >1.5 times ULN (except in case of Gilbert's syndrome); creatinine >1.5 times ULN; hemoglobin less than (<5.5) millimole per liter (mmol/L), white blood cell count (WBC) <2.5 * 10^9 per liter, or platelets <75 *10^9 per liter)
• Any suspicion of intra-articular infection
• Any known active infections that may compromise the immune system such as human immunodeficiency virus (HIV), Hepatitis B or C infection
• History of sarcoma and/or of other active malignancy within five years, except adequately treated basal cell or squamous cell carcinoma of the skin
• Open growth plate, as revealed by MRI
• Diagnostic arthroscopy after injury and within 4 weeks prior to treatment start

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck KGaA, Darmstadt, Germany

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Responsible

Role: STUDY_DIRECTOR

Merck KGaA, Darmstadt, Germany

Locations

Please contact the Merck KGaA Communication Center

Darmstadt, , Germany

Countries

Germany

Other Identifiers

EMR700692_003

Identifier Type: -

Identifier Source: org_study_id